AbTx Overview
- Year Founded
-
2023
- Status
-
Private
- Employees
-
8
- Latest Deal Type
-
Crowdfunding
- Latest Deal Amount
-
$786K
- Investors
-
1
AbTx General Information
Description
Developer of oncology treatments designed to treat incurable cancers. The company's platform utilizes enzymatic conjugation to create antibody fragment drug conjugates, providing patients with improved solid tumor penetration and reduced toxicity for the treatment of pancreatic and other cancers.
Contact Information
Website
abtx-bio.comCorporate Office
- 64 A Rue Sully
- 21000 Dijon
- France
Corporate Office
- 64 A Rue Sully
- 21000 Dijon
- France
AbTx Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 2. Equity Crowdfunding | 31-Mar-2026 | $786K | Completed | Startup | ||
| 1. Accelerator/Incubator | Completed | Startup |
AbTx Signals
AbTx Investors (1)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| DECA-BFC | Accelerator/Incubator |
AbTx FAQs
-
When was AbTx founded?
AbTx was founded in 2023.
-
Where is AbTx headquartered?
AbTx is headquartered in Dijon, France.
-
What is the size of AbTx?
AbTx has 8 total employees.
-
What industry is AbTx in?
AbTx’s primary industry is Drug Discovery.
-
Is AbTx a private or public company?
AbTx is a Private company.
-
What is the current valuation of AbTx?
The current valuation of AbTx is .
-
What is AbTx’s current revenue?
The current revenue for AbTx is .
-
How much funding has AbTx raised over time?
AbTx has raised $786K.
-
Who are AbTx’s investors?
DECA-BFC has invested in AbTx.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process